Centogene N.V.
General information
Centogene N.V.
Am Strande 7
18055 Rostock, Mecklenburg-Vorpommern
Germany
Contact person: Peter Bauer, Chief Medical and Genomic Officer
Company main phone: +49 (381) 80113400
Company main fax: +49 (381) 80113401
Website: https://www.centogene.com
Am Strande 7
18055 Rostock, Mecklenburg-Vorpommern
Germany
Contact person: Peter Bauer, Chief Medical and Genomic Officer
Company main phone: +49 (381) 80113400
Company main fax: +49 (381) 80113401
Website: https://www.centogene.com
| Year founded: | 2006 |
| Source of foundation: | Independent foundation |
| No. of employees: |
Worldwide: 384 |
Corporate description / mission:
CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. The company provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing. The company's CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics.The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports.
CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. The company provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing. The company's CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics.The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2019
Headquarters: HQ: Yes
IPO (year): 2019
Remarks on ownership / listings
CENTOGENE Delisted from Nasdaq.
CENTOGENE Delisted from Nasdaq.
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
| Distribution: |
|
Summary Products / Services / Technologies
Description of products:
Prenatal Testing
Newborn testing
Metabolic Testing
Hereditary Cancer Testing, etc.
Prenatal Testing
Newborn testing
Metabolic Testing
Hereditary Cancer Testing, etc.
Financing details
Fiscal year (end of) 2023
| Revenues: | USD 51.44M | |
| R&D expenses: | USD 11.00M | |
| Cash: | USD 20.68M |
| Total liabilities: | USD 104.75M | |
| No. of shares: | 29'000'100 | |
| Market cap. / valuation: | USD 9.43M |
© 2024 Biotechgate by Venture Valuation